Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer.
J Med Econ. 2021 Jan-Dec;24(1):1185-1193. doi: 10.1080/13696998.2021.1993864.
J Med Econ. 2021.
PMID: 34647849
Free article.
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T, Datz Abadi M, Chabrol Haas L, da Veiga CRP, de Vasconcelos Ferreira D, Jardim DL.
Engel Ayer Botrel T, et al. Among authors: chabrol haas l.
J Med Econ. 2021 Jan-Dec;24(1):291-298. doi: 10.1080/13696998.2021.1883034.
J Med Econ. 2021.
PMID: 33538203
Free article.
Item in Clipboard
Cite
Cite